Pfizer Financials

PFE Stock   12.21  0.15  1.24%   
You can utilize fundamental analysis to find out if Pfizer Inc CDR is mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We were able to break down and interpolate data for twenty-six available financial ratios for Pfizer Inc CDR, which can be compared to its competitors. The stock experiences a large bullish trend. Check odds of Pfizer to be traded at 13.43 in 90 days. Key indicators impacting Pfizer's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Operating Income18 B14.9 B
Fairly Up
Pretty Stable
  

Pfizer Stock Summary

Pfizer competes with Goodfood Market, Metalero Mining, NeXGold Mining, Mako Mining, and Sun Peak. Pfizer is entity of Canada. It is traded as Stock on NEO exchange.
Foreign Associates
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentCanada Stock View All
ExchangeNEO Exchange
ISINCA7170651060
Business Address66 Hudson Boulevard
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.pfizer.com
Phone212 733 2323
You should never invest in Pfizer without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Pfizer Stock, because this is throwing your money away. Analyzing the key information contained in Pfizer's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Pfizer Key Financial Ratios

Pfizer's financial ratios allow both analysts and investors to convert raw data from Pfizer's financial statements into concise, actionable information that can be used to evaluate the performance of Pfizer over time and compare it to other companies across industries.

Pfizer Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets154.2B181.5B197.2B226.5B213.4B204.2B
Other Current Liab12.1B26.7B23.4B20.5B19.7B19.9B
Other Liab29.9B26.6B22.6B23.3B21.0B21.3B
Net Tangible Assets(19.0B)(14.7B)2.8B916M1.1B1.1B
Net Debt36.5B35.1B34.5B68.0B62.6B51.5B
Retained Earnings90.4B103.4B125.7B118.4B116.7B116.6B
Accounts Payable4.3B5.6B6.8B6.7B5.6B5.9B
Cash1.8B1.9B416M2.9B1.0B1.6B
Other Assets18.0B5.8B8.2B16.9B19.4B11.7B
Long Term Debt35.6B34.8B31.9B60.5B56.7B45.2B
Net Receivables7.9B11.5B11.0B11.6B11.5B11.7B
Good Will49.6B49.2B51.4B67.8B68.5B62.6B
Inventory8.0B9.1B9.0B10.2B10.9B9.7B
Other Current Assets3.6B3.8B5.0B5.3B4.3B4.6B
Total Liab90.8B104.0B101.3B137.2B124.9B119.1B
Net Invested Capital101.5B114.2B130.5B159.9B151.9B138.0B
Short Long Term Debt2.7B2.2B2.9B10.3B6.9B5.7B
Total Current Assets35.1B59.7B51.3B43.3B50.4B50.7B
Capital Stock470M473M476M478M480M382.6M
Net Working Capital9.1B17.0B9.1B(4.5B)7.4B5.9B
Intangible Assets28.5B25.1B43.4B64.9B55.4B45.2B
Common Stock468M470M473M476M547.4M517.9M

Pfizer Key Income Statement Accounts

202020212022202320242025 (projected)
Tax Provision477M1.9B3.3B(1.1B)(28M)(26.6M)
Net Interest Income(1.4B)(1.3B)(987M)(585M)(2.5B)(2.4B)
Interest Income73M36M251M1.6B545M485.3M
Interest Expense1.4B1.3B1.2B2.2B3.1B1.9B
Total Revenue41.9B81.3B100.3B59.6B63.6B71.0B
Gross Profit33.2B50.5B66.0B34.6B45.8B49.3B
Operating Income8.8B20.2B37.3B4.4B14.9B18.0B
Ebit8.1B9.8B27.0B39.0B44.8B47.1B
Research Development9.4B13.8B11.4B10.7B10.8B11.4B
Ebitda25.3B13.7B30.8B39.6B45.5B28.4B
Cost Of Revenue8.7B30.8B34.3B25.0B17.9B21.7B
Income Before Tax7.5B24.3B34.7B1.1B8.0B12.0B
Net Income9.6B22.0B31.4B2.1B8.0B11.5B
Income Tax Expense583M370M1.9B3.3B3.8B4.0B

Pfizer Key Cash Accounts

202020212022202320242025 (projected)
Change To Inventory(778M)(1.1B)592M(1.2B)(854M)(896.7M)
Investments(1.7B)(19.5B)6.7B(25.7B)2.7B2.8B
Change In Cash475M159M(1.5B)1.9B(1.8B)(1.7B)
Net Borrowings8.8B(12.8B)(1.1B)(3.5B)(3.2B)(3.0B)
Free Cash Flow11.6B29.9B26.0B8.2B9.8B12.5B
Depreciation4.7B5.1B5.0B6.1B7.0B6.3B
Other Non Cash Items(2.3B)(4.7B)(400M)(2.6B)(2.3B)(2.4B)
Dividends Paid8.4B8.7B9.0B9.2B9.5B9.6B
Capital Expenditures2.2B2.7B3.2B3.9B2.9B3.0B
Net Income9.6B22.0B31.4B2.1B8.0B11.5B
End Period Cash Flow1.8B2.0B468M3.3B1.1B1.8B
Change To Netincome(5.3B)887M(7.3B)(2.7B)(2.4B)(2.5B)

Pfizer Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Pfizer's current stock value. Our valuation model uses many indicators to compare Pfizer value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pfizer competition to find correlations between indicators driving Pfizer's intrinsic value. More Info.
Pfizer Inc CDR is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about  0.37  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Pfizer Inc CDR is roughly  2.67 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Pfizer by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Pfizer's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Pfizer Inc CDR Systematic Risk

Pfizer's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Pfizer volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Pfizer Inc CDR correlated with the market. If Beta is less than 0 Pfizer generally moves in the opposite direction as compared to the market. If Pfizer Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Pfizer Inc CDR is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Pfizer is generally in the same direction as the market. If Beta > 1 Pfizer moves generally in the same direction as, but more than the movement of the benchmark.

Pfizer Inc CDR Total Assets Over Time

Pfizer March 1, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Pfizer help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Pfizer Inc CDR. We use our internally-developed statistical techniques to arrive at the intrinsic value of Pfizer Inc CDR based on widely used predictive technical indicators. In general, we focus on analyzing Pfizer Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pfizer's daily price indicators and compare them against related drivers.

Other Information on Investing in Pfizer Stock

Pfizer financial ratios help investors to determine whether Pfizer Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pfizer with respect to the benefits of owning Pfizer security.